Goldman Bio is a leading brand specializing in the development, integration, and commercialization of Israeli Life Science technologies, with a particular focus on the field of personalized medicine, specifically cancer. This innovative approach to medical treatment offers new solutions and creative implementations of existing ones. Goldman Bio's portfolio consists of a network of companies that deal with various aspects of personalized medicine, ranging from diagnostics to healthcare technologies.

With an experienced management team and a robust infrastructure, Goldman Bio has successfully identified and selected breakthrough technologies in specialized fields, transforming them into valuable commercial assets. Their vision is to provide a technology transfer infrastructure for Israeli technologies in Life Sciences and Personalized Medicine. Goldman Bio establishes close partnerships with academic institutions, ensuring access to leading international researchers and facilitating the integration of academia with the private sector.

By leveraging the expertise of academic researchers and scientific advisory boards, Goldman Bio maximizes commercial value while identifying and pursuing opportunities for additional technologies and business ventures